These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 15728186

  • 21. Difference in IgA1 O-glycosylation between IgA deposition donors and IgA nephropathy recipients.
    Nakazawa S, Imamura R, Kawamura M, Kato T, Abe T, Namba T, Iwatani H, Yamanaka K, Uemura M, Kishikawa H, Nishimura K, Oka K, Tajiri M, Wada Y, Nonomura N.
    Biochem Biophys Res Commun; 2019 Jan 22; 508(4):1106-1112. PubMed ID: 30553446
    [Abstract] [Full Text] [Related]

  • 22. IgA1 hinge-region clustered glycan fidelity is established early during semi-ordered glycosylation by GalNAc-T2.
    Stewart TJ, Takahashi K, Whitaker RH, Raska M, Placzek WJ, Novak J, Renfrow MB.
    Glycobiology; 2019 Jul 01; 29(7):543-556. PubMed ID: 30759204
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. O-glycoforms of polymeric immunoglobulin A1 in the plasma of patients with IgA nephropathy are associated with pathological phenotypes.
    Yu G, Zhang Y, Meng B, Xie X, Wang Z, Ying W, Lv J, Zhang H.
    Nephrol Dial Transplant; 2021 Dec 31; 37(1):33-41. PubMed ID: 34152412
    [Abstract] [Full Text] [Related]

  • 25. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy.
    Barratt J, Smith AC, Feehally J.
    Nephrology (Carlton); 2007 Jun 31; 12(3):275-84. PubMed ID: 17498123
    [Abstract] [Full Text] [Related]

  • 26. Similarities between N-glycan glycoform of tonsillar IgA1 and that of aberrant IgA1 abundant in IgA nephropathy patient serum.
    Iwanami N, Iwase H, Takahashi N, Kato K, Itoh A, Takatani T, Makita S, Kobayashi Y, Okamoto M, Nakamura S, Hiki Y, Ishii M.
    J Nephrol; 2008 Jun 31; 21(1):118-26. PubMed ID: 18264945
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Methodological approaches to the analysis of IgA1 O-glycosylation in IgA nephropathy.
    Allen AC.
    J Nephrol; 1999 Jun 31; 12(2):76-84. PubMed ID: 10378662
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy.
    Novak J, Julian BA, Tomana M, Mestecky J.
    Semin Nephrol; 2008 Jan 31; 28(1):78-87. PubMed ID: 18222349
    [Abstract] [Full Text] [Related]

  • 31. O-linked glycosylation determines the nephritogenic potential of IgA rheumatoid factor.
    Kihara M, Ito K, Nakata J, Otani M, Tran NL, Morito N, Takahashi S, Wada Y, Izui S.
    J Am Soc Nephrol; 2014 Jun 31; 25(6):1282-90. PubMed ID: 24511137
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of IgA1 O-glycosylation in Henoch-Schönlein Purpura Nephritis Using Mass Spectrometry.
    Nakazawa S, Imamura R, Kawamura M, Kato T, Abe T, Iwatani H, Yamanaka K, Uemura M, Kishikawa H, Nishimura K, Tajiri M, Wada Y, Nonomura N.
    Transplant Proc; 2019 Jun 31; 51(5):1481-1487. PubMed ID: 31084922
    [Abstract] [Full Text] [Related]

  • 33. Diagnostic Potential of Plasma IgA1 O-Glycans in Discriminating IgA Nephropathy From Other Glomerular Diseases and Healthy Participants.
    Zhang S, Sun H, Zhang Z, Li M, Guo Z, Ye W, Cai G, Sun W, Li M.
    Front Mol Biosci; 2022 Jun 31; 9():871615. PubMed ID: 35445079
    [Abstract] [Full Text] [Related]

  • 34. Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS.
    Klapoetke SC, Zhang J, Becht S.
    J Pharm Biomed Anal; 2011 Nov 01; 56(3):513-20. PubMed ID: 21752569
    [Abstract] [Full Text] [Related]

  • 35. N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.
    Stuchlova Horynova M, Vrablikova A, Stewart TJ, Takahashi K, Czernekova L, Yamada K, Suzuki H, Julian BA, Renfrow MB, Novak J, Raska M.
    Nephrol Dial Transplant; 2015 Feb 01; 30(2):234-8. PubMed ID: 25281698
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Evaluation of the specific structures of IgA1 hinge glycopeptide in 30 IgA nephropathy patients by mass spectrometry.
    Odani H, Yamamoto K, Iwayama S, Iwase H, Takasaki A, Takahashi K, Fujita Y, Sugiyama S, Hiki Y.
    J Nephrol; 2010 Feb 01; 23(1):70-6. PubMed ID: 20091489
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry.
    Odani H, Hiki Y, Takahashi M, Nishimoto A, Yasuda Y, Iwase H, Shinzato T, Maeda K.
    Biochem Biophys Res Commun; 2000 Apr 29; 271(1):268-74. PubMed ID: 10777713
    [Abstract] [Full Text] [Related]

  • 40. Increased sialylation of polymeric immunoglobulin A1: mechanism of selective glomerular deposition in immunoglobulin A nephropathy?
    Leung JC, Poon PY, Lai KN.
    J Lab Clin Med; 1999 Feb 29; 133(2):152-60. PubMed ID: 9989767
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.